Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Allogene Therapeutics Inc

Atara Biotherapeutics

Cellectis SA

CRISPR Therapeutics

Gilead Sciences

Novartis

Pfizer

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.

Regenerative Medicines: Universal Cell Therapy Gaining Momentum

AbbVie

Merck

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn't mean that they don't have occasional colossal losses; they do (like Peltz's recent General Electric losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Bristol Myers Squibb Company (NYSE:BMY).

Do Hedge Funds Love Bristol Myers Squibb Company (BMY) As Much As Buffett Does?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Generation PMCA recently released its Q3 2020 Investor Letter. The fund is managed by co-founders Randall Abramson and Herb Abramson. The investment firm serves its clients through two distinct areas: Portfolio Management and Capital Advisory services. You should check out Generation PMCA's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Is Bristol-Myers Squibb (BMY) a Smart Long-term Buy?

Schrodinger 

Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in milestone payments and royalties. Schrödinger, which offers a physics-based software platform that can speed up drug development and lower costs, will receive $55 million upfront.

Schrödinger in drug development agreement with Bristol Myers worth up to $2.7 billion in milestone and royalty payments

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas. The multi-year collaboration will combine Schrödinger's leading physics-based computational platform and drug discovery capabilities with Bristol Myers Squibb's expe

Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.

Warren Buffett Just Bought These Stocks

BMY is one of the most successful pharma giants when it comes to sales and cash flow-boosting mergers and acquisitions. BMY hasn't cut it since at least 1985, and it's working with a 13-year growth streak right now.

Bristol Myers Squibb: A Classic Buffett Style 'Fat Pitch'

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Wolfe Research Healthcare Conference (Transcript)

Bristol-Myers Squibb's acquisition of MyoKardia is exciting, especially its all cash notion that can drive shareholder value. The company has an impressive portfolio of assets, and has upped its 2020 non-GAAP guidance, with exciting 2021 guidance.

Bristol-Myers Squibb Continues On Its Path To Becoming The Next Quarter Trillion-Dollar Company

Warren Buffett's Berkshire Hathaway plowed more than $5 billion in total into AbbVie, Bristol Myers Squibb, Merck, and Pfizer in the third quarter. Close followers of the company won't be surprised, as Buffett has been mulling a bet on the pharmaceutical sector for more than 20 years. "You could've just bought the whole industry and done very well," the famed investor said at Berkshire's annual shareholder meeting in 1997. He was referring to the downturn in drug stocks in the early 1990s, sparked by President Bill Clinton's proposed healthcare reforms. "We didn't do it. It was a mistake."

Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years

The Oracle of Omaha and his investing lieutenants knew what they were doing in buying AbbVie, BMS, Merck, and Pfizer.

Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks

MyoKardia

The deal was a big bet on one promising pipeline drug.

Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia

Berkshire Hathaway bought $5.7bn worth of shares in four companies in third quarter

Warren Buffett makes big investment in US pharmaceutical firms

Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.

Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.

Has Buffett Become an Expert on Big Pharma?

Johnson & Johnson

Regeneron Pharmaceuticals

Sanofi

SPDR S&P Pharmaceuticals ETF

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

Let's see if Bristol Myers Squibb Company (BMY) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Now Choose Bristol Myers (BMY) Stock?

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb. The MyoKardia team has revolutionized

Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.

AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter

Veeva Systems

PLEASANTON, Calif.--(BUSINESS WIRE)-- #VeevaSummitEU--Bristol Myers Squibb is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers' needs.

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market

PRINCETON, N.J.--(BUSINESS WIRE)--The BMS Foundation and National Medical Fellowships launch $100 million program to help increase diversity and inclusion in clinical trials

The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials

News for Bristol-Myers Stock (BMY)